Adagrasib for KRAS G12C lung cancer, alone or with pembrolizumab
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial studies adagrasib (an anti-cancer drug) either alone or with pembrolizumab (an immunotherapy) in people with advanced lung cancer that has a KRAS G12C mutation. It aims to shrink tumors and improve outcomes, including for people without urgent brain treatment needs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced (unresectable or metastatic) non-small cell lung cancer (NSCLC) with a confirmed KRAS G12C mutation
- PD-L1 blood/tissue testing meets the trial threshold (any level for the Phase 2 part; PD-L1 TPS ≥ 50% for the Phase 3 part)
- You have disease that can be measured on scans for the Phase 3 part
- Your brain scan shows either no brain metastases, or brain metastases that don’t require immediate radiation/surgery and are stable
- You have not had prior medicines for advanced NSCLC, including chemotherapy, immune checkpoint inhibitors, or KRAS G12C-targeting drugs
- For the Phase 2 part, you do not have active brain metastases; for the Phase 3 part, you cannot have certain brain findings or ongoing high-dose steroid needs
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests new drugs that target specific RAS mutations in advanced non-small cell lung cancer. It's for people whose cancer has a KRAS G12C, G12D, or other RAS mutation and who have already tried standard treatments.
This trial tests if adding the targeted drug adagrasib to standard immunotherapy and chemotherapy helps people with a specific KRAS G12C mutation in non-squamous non-small cell lung cancer that has spread. It is for people who have not had previous treatment for advanced disease.
This study tests a targeted pill (adagrasib) combined with focused radiation to the brain (SRS) for people with KRAS G12C-mutated lung cancer that has spread to the brain. The goal is to see if this combination can control brain tumors while treating the rest of the body.
This trial combines a vaccine called CIMAvax-EGF with a KRAS G12C inhibitor to treat advanced lung cancer with a specific genetic change. The goal is to see if adding this vaccine helps the targeted therapy work better or longer.
This trial tests a new drug called HS-10370 combined with other anti-cancer treatments for people with advanced lung cancer that has a specific genetic change (KRAS G12C). The goal is to see if this combination can shrink or control tumors better than other options.
This trial tests a new pill called Garsorasib for people with advanced non-small cell lung cancer that has a specific gene change called KRAS G12C. It aims to see if the drug can shrink tumors or slow cancer growth in people who haven't had treatment yet.
Hear when a new Advanced Non-Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.